國家衛生研究院 NHRI:Item 3990099045/12766
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 856537      Online Users : 685
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version


    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/12766


    Title: Metformin use is associated with a lower risk of inflammatory bowel disease in patients with type 2 diabetes mellitus
    Authors: Tseng, CH
    Contributors: National Institute of Environmental Health Sciences
    Abstract: AIM: To compare the risk of inflammatory bowel disease (IBD) between ever users and never users of metformin. METHODS: Patients with newly diagnosed type 2 diabetes mellitus from 1999 to 2005 were enrolled from Taiwan's National Health Insurance. A total of 340,211 ever users and 24,478 never users who were free from IBD on January 1, 2006 were followed up until December 31, 2011. Hazard ratios were estimated by Cox regression incorporated with the inverse probability of treatment weighting using propensity score. RESULTS: New-onset IBD was diagnosed in 6466 ever users and 750 never users. The respective incidence rates were 412.0 and 741.3 per 100,000 person-years and the hazard ratio for ever versus never users was 0.55 (95% confidence interval: 0.51-0.60). A dose-response pattern was observed while comparing the tertiles of cumulative duration of metformin therapy to never users. The respective hazard ratios for the first (< 26.0 months), second (26.0-58.3 months) and third (> 58.3 months) tertiles were 1.00 (0.93-1.09), 0.57 (0.52-0.62) and 0.24 (0.22-0.26). While patients treated with oral antidiabetic drugs (OADs) without metformin were treated as a referent group, the hazard ratios for patients treated with OADs with metformin, with insulin without metformin (with/without other OADs) and with insulin and metformin (with/without other OADs) were 0.52 (0.42-0.66), 0.95 (0.76-1.20) and 0.50 (0.40-0.62), respectively. CONCLUSION: A reduced risk of IBD is consistently observed in patients with type 2 diabetes mellitus who have been treated with metformin.
    Date: 2021-01
    Relation: Journal of Crohn's and Colitis. 2021 Jan;15(1):64-73.
    Link to: http://dx.doi.org/10.1093/ecco-jcc/jjaa136
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1873-9946&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000646876300009
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85090064284
    Appears in Collections:[Others] Periodical Articles

    Files in This Item:

    File Description SizeFormat
    PUB32604412.pdf827KbAdobe PDF301View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback